InflaRx N.V. (IFRX)
NASDAQ: IFRX · Real-Time Price · USD
1.730
-0.100 (-5.46%)
Feb 24, 2025, 11:59 AM EST - Market open
InflaRx Revenue
InflaRx had revenue of 123.82K EUR in the quarter ending September 30, 2024, with 103.64% growth. This brings the company's revenue in the last twelve months to 168.50K, up 177.12% year-over-year. In the year 2023, InflaRx had annual revenue of 63.09K.
Revenue (ttm)
168.50K EUR
Revenue Growth
+177.12%
P/S Ratio
574.95
Revenue / Employee
2,709 EUR
Employees
62
Market Cap
101.87M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
IFRX News
- 5 days ago - InflaRx Announces Closing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants - GlobeNewsWire
- 10 days ago - InflaRx Announces Pricing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants - GlobeNewsWire
- 10 days ago - InflaRx Announces Public Offering of Ordinary Shares and Pre-Funded Warrants - GlobeNewsWire
- 4 weeks ago - InflaRx Announces Participation in Guggenheim SMID Cap Biotech Conference - GlobeNewsWire
- 5 weeks ago - InflaRx Receives European Commission Approval for GOHIBIC® (vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS) - GlobeNewsWire
- 2 months ago - InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904 - GlobeNewsWire
- 3 months ago - InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome - GlobeNewsWire
- 3 months ago - InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire